A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

Br J Cancer · 2012 · PMC3419962 · PMID 22814578

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The combined incidence of HFS-related AEs (‘HFS’ or ‘rash hand foot skin reaction’) showed a trend in favour of pyridoxine use: any grade was 51% vs 53% (odds ratio 0.93, 95% CI 0.43–2.0) whereas grade 3/4 was 9% vs 17% (odds ratio 0.51, 95% CI 0.15–1.6).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.